Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost
ConditionOpen Angle Glaucoma
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorPrairie Eye Center
About this trial
A randomized, multi-site, parallel-group, prospective study of patients who are adults with a diagnosis of mild to moderate open-angle glaucoma (OAG), currently on an on-label use of combination topical medication of Cosopt and Latanoprost for a minimum of 1 month.
Eligibility criteria
Qualifiers
Optic disc or retinal nerve fiber layer (RNFL) structural abnormalities
Diffuse or focal narrowing, or notching, of the optic disc rim, especially at the inferior or superior poles, which forms the basis for the ISNT rule
Progressive narrowing of the neuroretinal rim with an associated increase in cupping of the optic disc
Diffuse or localized abnormalities of the parapapillary RNFL, especially at the inferior or superior poles
Disqualifiers
Patients with prior ocular procedures or intraocular surgery within 1 year prior to baseline (e.g. cataract surgery).
Patients with prior history of glaucoma surgeries or laser treatment except patients with history of SLT >1 yr prior to baseline.
Contraindications or known hypersensitivity to any or all the study medications including Rocklatan, Simbrinza, Cosopt and Latanoprost or related class of drugs.
Patients with known history or presence of uncontrolled systemic diseases including diseases that, in investigator's opinion, may make it unsafe or undesirable for the subject to participate in the study and/ or limit adherence.
Trial design
Treatments tested in this trial
- Simbrinza 0.2%-1% Ophthalmic Suspension
- Rocklatan 0.02%-0.005% Ophthalmic Solution
- Cosopt PF 2%-0.5% Ophthalmic Solution
- Latanoprost 0.005% Ophthalmic Solution
Treatment groups
70 Participants
are divided into 2 treatment groupsSponsors and collaborators
Prairie Eye Center
Lead sponsor
Sengi
Collaborator
Source ClinicalTrials.gov